[Role of Galectin-9 and Sonic Hedgehog Expressions in the Early Diagnosis and Prognosis of Colorectal Cancer].
[OBJECTIVE] To investigate the association between the expression levels of galectin-9 and sonic hedgehog () and the risk of occurrence and prognosis in patients with colorectal cancer (CRC).
- 95% CI 0.751-0.868
- OR 4.609
APA
He Q, Liu X, et al. (2026). [Role of Galectin-9 and Sonic Hedgehog Expressions in the Early Diagnosis and Prognosis of Colorectal Cancer].. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 57(1), 217-223. https://doi.org/10.12182/20260160603
MLA
He Q, et al.. "[Role of Galectin-9 and Sonic Hedgehog Expressions in the Early Diagnosis and Prognosis of Colorectal Cancer].." Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, vol. 57, no. 1, 2026, pp. 217-223.
PMID
41834986
Abstract
[OBJECTIVE] To investigate the association between the expression levels of galectin-9 and sonic hedgehog () and the risk of occurrence and prognosis in patients with colorectal cancer (CRC).
[METHODS] A total of 210 patients with CRC treated at Qingdao Traditional Chinese Medicine Hospital between May 2020 and May 2022 were retrospectively included. The expressions of galectin-9 and in tumor tissues were measured. Logistic regression was used to analyze the relationship between galectin-9/ expression and CRC risk. Receiver operating characteristic (ROC) curves were plotted to evaluate the predictive value of galectin-9 and for CRC risk and prognosis.
[RESULTS] The expression levels of galectin-9 and differed significantly between cancer tissues and adjacent normal tissues (<0.05). ROC analysis showed that the AUCs for galectin-9 and in evaluating CRC risk were 0.809 (95% CI: 0.751-0.868) and 0.865 (95% CI: 0.817-0.912), respectively. Galectin-9 expression was lower in patients with T stage, N stage, M stage, or poor differentiation (<0.05), whereas SHH expression was higher in these patients(<0.05). Galectin-9 expression was negatively correlated with expression and TNM stage (=－0.184 and －0.362, respectively; <0.001). expression was positively correlated with TNM stage ( = 0.407, < 0.001). Significant differences in galectin-9 and expression were observed between patients with poor prognosis and those with good prognosis (< 0.05). Logistic regression analysis indicated that T stage (OR= 4.609, 95% CI: 1.461-14.535), poor differentiation (OR=3.337, 95% CI: 1.297-8.582), and high SHH expression (OR= 2.067, 95% CI: 1.162-3.678) were risk factors for poor prognosis (< 0.05), while high galectin-9 expression (OR = 0.652, 95% CI: 0.437-0.975) was a protective factor (< 0.05). The AUCs of galectin-9 and for evaluating CRC prognosis were 0.769 (95% CI: 0.550-0.798) and 0.734 (95% CI: 0.603-0.866), respectively.
[CONCLUSION] Galectin-9 and SHH are lowly and highly expressed, respectively, in CRC. Their expression levels are associated with tumor differentiation, invasion, and metastasis, and hold predictive value for the risk and prognosis of CRC patients.
[METHODS] A total of 210 patients with CRC treated at Qingdao Traditional Chinese Medicine Hospital between May 2020 and May 2022 were retrospectively included. The expressions of galectin-9 and in tumor tissues were measured. Logistic regression was used to analyze the relationship between galectin-9/ expression and CRC risk. Receiver operating characteristic (ROC) curves were plotted to evaluate the predictive value of galectin-9 and for CRC risk and prognosis.
[RESULTS] The expression levels of galectin-9 and differed significantly between cancer tissues and adjacent normal tissues (<0.05). ROC analysis showed that the AUCs for galectin-9 and in evaluating CRC risk were 0.809 (95% CI: 0.751-0.868) and 0.865 (95% CI: 0.817-0.912), respectively. Galectin-9 expression was lower in patients with T stage, N stage, M stage, or poor differentiation (<0.05), whereas SHH expression was higher in these patients(<0.05). Galectin-9 expression was negatively correlated with expression and TNM stage (=－0.184 and －0.362, respectively; <0.001). expression was positively correlated with TNM stage ( = 0.407, < 0.001). Significant differences in galectin-9 and expression were observed between patients with poor prognosis and those with good prognosis (< 0.05). Logistic regression analysis indicated that T stage (OR= 4.609, 95% CI: 1.461-14.535), poor differentiation (OR=3.337, 95% CI: 1.297-8.582), and high SHH expression (OR= 2.067, 95% CI: 1.162-3.678) were risk factors for poor prognosis (< 0.05), while high galectin-9 expression (OR = 0.652, 95% CI: 0.437-0.975) was a protective factor (< 0.05). The AUCs of galectin-9 and for evaluating CRC prognosis were 0.769 (95% CI: 0.550-0.798) and 0.734 (95% CI: 0.603-0.866), respectively.
[CONCLUSION] Galectin-9 and SHH are lowly and highly expressed, respectively, in CRC. Their expression levels are associated with tumor differentiation, invasion, and metastasis, and hold predictive value for the risk and prognosis of CRC patients.
MeSH Terms
Humans; Hedgehog Proteins; Prognosis; Galectins; Colorectal Neoplasms; Male; Female; Middle Aged; Retrospective Studies; Aged; Early Detection of Cancer; Adult; ROC Curve; Biomarkers, Tumor
같은 제1저자의 인용 많은 논문 (5)
- The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study.
- Tailoring imaging probes for defining glioma invasive margins: Tracing the molecular footprints of cancer cells.
- Functional and metabolic dysbiosis of the gut microbiome in the tumoral immune microenvironment of hepatocellular carcinoma.
- Silk fibroin-based nanocarriers for anticancer drug delivery: advances, mechanisms, and future perspectives.
- Molecular Mechanisms Underlying the Anti-Tumor Activity of Lotus-Derived Alkaloids in Breast Cancer.